PT  - JOURNAL ARTICLE
AU  - Nayak, Lakshmi
AU  - Molinaro, Annette M
AU  - Peters, Katherine B.
AU  - Clarke, Jennifer L.
AU  - Jordan, Justin T
AU  - de Groot, John F.
AU  - Nghiemphu, Phioanh Leia
AU  - Kaley, Thomas J
AU  - Colman, Howard
AU  - McCluskey, Christine
AU  - Gaffey, Sarah
AU  - Smith, Timothy
AU  - Cote, David J.
AU  - Severgnini, Mariano
AU  - Yearley, Jennifer H
AU  - Zhao, Qing
AU  - Blumenschein, Wendy M
AU  - Duda, Dan G
AU  - Muzikansky, Alona
AU  - Jain, Rakesh K.
AU  - Wen, Patrick Y.
AU  - Reardon, David A.
TI  - Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for recurrent glioblastoma patients
AID  - 10.1158/1078-0432.CCR-20-2500
DP  - 2020 Jan 01
TA  - Clinical Cancer Research
PG  - clincanres.2500.2020
4099  - http://clincancerres.aacrjournals.org/content/early/2020/11/14/1078-0432.CCR-20-2500.short
4100  - http://clincancerres.aacrjournals.org/content/early/2020/11/14/1078-0432.CCR-20-2500.full
AB  - Purpose: Vascular endothelial growth factor (VEGF) is upregulated in glioblastoma and may contribute to immunosuppression. We performed a phase 2 study of pembrolizumab alone or with bevacizumab in recurrent glioblastoma. Experimental Design: Eighty bevacizumab-naive, recurrent glioblastoma patients randomized to pembrolizumab with bevacizumab (cohort A, n=50) or pembrolizumab monotherapy (cohort B, n=30). The primary endpoint was six-month progression-free survival (PFS-6). Assessed biomarkers included evaluation of tumor PD-L1 expression, TIL density, immune activation gene expression signature and plasma cytokines. The Neurologic Assessment in Neuro-Oncology (NANO) scale was used to prospectively assess neurologic function. Results: Pembrolizumab alone or with bevacizumab was well tolerated but of limited benefit. For cohort A, PFS-6 was 26.0% (95% CI: 16.3, 41.5), median OS was 8.8 months (95% CI: 7.7, 14.2), ORR was 20% and median duration of response was 48 weeks. For cohort B, PFS-6 was 6.7% (95% CI: 1.7, 25.4), median OS was 10.3 months (95% CI: 8.5, 12.5) and ORR was 0%. Tumor immune markers were not associated with OS, but worsened OS correlated with baseline dexamethasone use and increased post-therapy plasma VEGF (cohort A) and mutant IDH1, unmethylated MGMT and increased baseline PlGF and sVEGFR1 levels (cohort B). The NANO scale contributed to overall outcome assessment. Conclusions: Pembrolizumab was ineffective as monotherapy and with bevacizumab for recurrent glioblastoma. The infrequent radiographic responses to combinatorial therapy were durable. Tumor immune biomarkers did not predict outcome. Baseline dexamethasone use and tumor MGMT warrant further study as potential biomarkers in GBM immunotherapy trials.